Abstract
Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Eating
-
Exenatide
-
Gastric Inhibitory Polypeptide / agonists*
-
Glucagon-Like Peptide 1 / administration & dosage
-
Glucagon-Like Peptide 1 / analogs & derivatives*
-
Glucagon-Like Peptide 1 / pharmacology
-
Glucagon-Like Peptide-1 Receptor
-
Humans
-
Hyperglycemia / drug therapy*
-
Hyperglycemia / metabolism
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / pharmacology*
-
Incretins / therapeutic use*
-
Liraglutide
-
Obesity / drug therapy*
-
Obesity / metabolism
-
Peptides / administration & dosage
-
Peptides / pharmacology*
-
Receptors, Glucagon / agonists*
-
Satiation / drug effects
-
Signal Transduction / drug effects
-
Venoms / administration & dosage
-
Venoms / pharmacology*
-
Weight Loss / drug effects*
Substances
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Incretins
-
Peptides
-
Receptors, Glucagon
-
Venoms
-
Gastric Inhibitory Polypeptide
-
Liraglutide
-
Glucagon-Like Peptide 1
-
Exenatide